SELLAS Life Sciences (SLS) Interest Coverage Ratio (2011 - 2026)
SELLAS Life Sciences' (SLS) quarterly Interest Coverage Ratio came in at 1.59 in Q1 2026, up 94.74% year-on-year from 0.82 in Q1 2025, and up 98.07% on a QoQ basis from 82.55 in Q4 2025.
SELLAS Life Sciences (SLS) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 14 years of Interest Coverage Ratio data on file, last reported at 1.59 in Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 94.74% year-over-year to 1.59 in Q1 2026; TTM through Mar 2026 was 5.42, a 90.29% increase from a year earlier, with the FY2025 full-year figure at 1.24, up 18.03% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 1.59, up from 82.55 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for SLS reached as high as 1.59 in Q1 2026 and fell as low as 167.35 in Q1 2022.
- Historically, Interest Coverage Ratio has averaged 71.72 across 5 years, with a median of 76.21 in 2024.
- Across the five-year window, Interest Coverage Ratio sank 645.43% in 2022 and soared 95.61% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 47.23 in 2022, then sank by 73.13% to 81.77 in 2023, then advanced by 15.4% to 69.18 in 2024, then slipped by 19.33% to 82.55 in 2025, then jumped by 98.07% to 1.59 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 1.59 in Q1 2026, 82.55 in Q4 2025, and 35.42 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - | -1.59 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.59 |
| Dec 31, 2025 | -82.55 |
| Sep 30, 2025 | -35.42 |
| Jun 30, 2025 | -3.34 |
| Mar 31, 2025 | -30.32 |
| Dec 31, 2024 | -69.18 |
| Sep 30, 2024 | -73.29 |
| Jun 30, 2024 | -76.21 |
| Mar 31, 2024 | -96.45 |
| Dec 31, 2023 | -81.77 |
| Sep 30, 2023 | -93.61 |
| Jun 30, 2023 | -90.50 |
| Mar 31, 2023 | -112.81 |
| Dec 31, 2022 | -47.23 |
| Sep 30, 2022 | -71.46 |
| Jun 30, 2022 | -86.23 |
| Mar 31, 2022 | -167.35 |
| Dec 31, 2021 | -116.19 |
| Sep 30, 2021 | -69.77 |
| Jun 30, 2021 | -44.53 |